1702 related articles for article (PubMed ID: 8597337)
1. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
[TBL] [Abstract][Full Text] [Related]
2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma].
Elsässer-Beile U; Garbe C; Stadler R; Drews H; Schöpf E
Hautarzt; 1989 May; 40(5):266-70. PubMed ID: 2737901
[TBL] [Abstract][Full Text] [Related]
4. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
[TBL] [Abstract][Full Text] [Related]
5. [Exacerbation of psoriasis during alpha-interferon therapy].
Hartmann F; von Wussow P; Deicher H
Dtsch Med Wochenschr; 1989 Jan; 114(3):96-8. PubMed ID: 2912680
[TBL] [Abstract][Full Text] [Related]
6. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
9. Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion.
Ludwig CU; Ludwig-Hagemann R; Obrist R; Obrecht JP; Holdener EE; Sutter-Melde C
Onkologie; 1990 Apr; 13(2):117-22. PubMed ID: 2197582
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
11. More on cutaneous reactions to recombinant cytokine therapy.
Le Gal FA; Paul C; Chemaly P; Dubertret L
J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
[No Abstract] [Full Text] [Related]
12. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
Johnson DM; Hayat SQ; Burton GV
J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
[No Abstract] [Full Text] [Related]
13. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury AF; El Sayed F; Bazex J
Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
[No Abstract] [Full Text] [Related]
14. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma.
Dummer R; Hauschild A; Henseler T; Burg G
Lancet; 1998 Sep; 352(9131):908-9. PubMed ID: 9743016
[No Abstract] [Full Text] [Related]
15. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
16. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
[No Abstract] [Full Text] [Related]
17. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
Hanson DS; Leggette CT
Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
[No Abstract] [Full Text] [Related]
18. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.
Sertoli MR; Bernengo MG; Ardizzoni A; Brunetti I; Falcone A; Vidili MG; Cusimano MP; Appino A; Doveil G; Fortini C
Oncology; 1989; 46(2):96-8. PubMed ID: 2710482
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
20. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
